TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7477994
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisone (20 mg daily for the first week and 10 mg daily for the second week)
Study: 2142574
Drug: Single-dose ethinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ethinyl estradiol from Femovan
Study: 2142574
Drug: Single-dose ethinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ethinyl estradiol from Marvelon
Study: 19678952
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg human AAT (Prolastin) weekly infusions
Study: 17367973
Drug: Injection protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection protocol used in this study
Study: 15311314
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and 250 mg of metronidazole (3 times a day for 10 days)
Study: 9765722
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation therapy (lumpectomy with axillary dissection)
Study: 3035002
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg i.v.)
Study: 24006670
Drug: Transcutaneous acupoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous acupoint electrical stimulation (TAES) combined with target controlled infusion of Propofol
Study: 24006670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (target controlled infusion of Propofol without TAES)
Study: 17029347
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies (hemodynamic maneuvers, magnesium, statins, endothelin antagonists, steroid drugs, anticoagulant/antiplatelet agents, intrathecal fibrinolytic drugs)
Study: 17029347
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel antagonists (nicardipine)
Study: 17029347
Drug: Rescue therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue therapy (balloon angioplasty, intraarterial vasodilating agents)
Study: 27253231
Drug: 24-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein, recombinant 0.24 MG/ML [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour infusion of 20 mg nafamostat mesilate
Study: 27253231
Drug: 6-hour infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-hour infusion of 20 mg nafamostat mesilate
Study: 27253231
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (6-hour infusion)
Study: 21847539
Drug: Topical amitriptyline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amitriptyline, ketamine, and lidocaine (AKL) applied three times a day until 2 weeks post-radiotherapy.
Study: 8771420
Drug: Early endoscopy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endoscopy combined with endoscopic therapy for patients with bloody aspirate
Study: 1466212
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (1 mg.kg‐1)
Study: 25295434
Drug: Specialized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized treatment (CAU + PEP + psychiatric consultation or cognitive‐behavioral therapy)
Study: 25295434
Drug: Primary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary treatment (CAU or CAU + PEP)
Study: 21742445
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment + naltrexone
Study: 20675864
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy laser therapy (Group A, n=35)
Study: 20675864
Drug: Vacuum therapy
Normalized name: Rapport Vacuum Therapy Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum therapy combined with Ultra Reiz current (Group C, n=32)
Study: 20675864
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (Group B, n=27)
Study: 15749735
Drug: Magnesium (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (80 mg kg(‐1) followed by infusion at 2 g h(‐1))
Study: 12884643
Drug: Statins (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (specific type not mentioned, but atorvastatin is referenced for cost comparison)
Study: 8876359
Drug: Inosine pranobex
Normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine pranobex (1 g orally 3 times a day for 6 weeks)
Study: 6696302
Drug: Oxacillin 500
Normalized name: oxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin 500 mg qid for five days
Study: 31314106
Drug: Inhalation Injury
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Injury (INHI)
Study: 31314106
Drug: No Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Inhalation Injury (No INHI)
Study: 28699267
Drug: Lucerastat 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucerastat 1,000 mg b.i.d. for 12 weeks
Study: 28699267
Drug: Enzyme Replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme Replacement Therapy (ERT) only
Study: 26758265
Drug: Arthroscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic surgery (arthroscopic debridement and partial resection of degenerative knee tissues) in addition to optimised non-operative therapy
Study: 26758265
Drug: Optimised non-operative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised non-operative therapy only
Study: 24022643
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac 0.5 % solution
Study: 24022643
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide 250 mg/day
Study: 24022643
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no agent)
Study: 20669670
Drug: Ginaton 1
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginaton 1 mg/kg
Study: 17505565
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PPI, clarithromycin, amoxicillin)
Study: 17505565
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PPI, clarithromycin, metronidazole)
Study: 17505565
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PPI, amoxicillin, metronidazole)
Study: 17505565
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (PPI, bismuth, metronidazole, tetracycline) for 7-10 days
Study: 15017231
Drug: Intraplaque electromotive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraplaque electromotive administration of 5 mg verapamil and 8 mg dexamethasone
Study: 15017231
Drug: Electromotive administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electromotive administration of 2% lidocaine
Study: 9241405
Drug: High phenylalanine
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High phenylalanine supplement over 3 months
Study: 3329102
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg/day before breakfast for six months
Study: 3329102
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day before breakfast for six months
Study: 3329102
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg/day before breakfast from 7th to 12th month
Study: 21539403
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of lisdexamfetamine dimesylate 50 mg
Study: 21539403
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of lisdexamfetamine dimesylate 50 mg
Study: 8566979
Drug: 0.15% cream
Normalized name: ROFLUMILAST 0.15% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% cream
Study: 8566979
Drug: 0.3% cream
Normalized name: ROFLUMILAST 0.3% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% cream
Study: 8566979
Drug: 0.5% solution
Normalized name: VueBlu 0.5% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% solution
Study: 2528439
Drug: Benzoyl peroxide/potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide/potassium hydroxyquinoline sulphate cream with hydrocortisone
Study: 2528439
Drug: Benzoyl peroxide/potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzoyl peroxide/potassium hydroxyquinoline sulphate cream without hydrocortisone
Study: 2528439
Drug: Aqueous astringent
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous astringent cream base alone
Study: 2528439
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide alcoholic gel
Study: 21927856
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (200 ml h(‐1) of a mixture of 18 amino acids)
Study: 21927856
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (200 ml h(‐1))
Study: 21927856
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion and saline infusion
Study: 7970548
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol and atropine combined
Study: 3310418
Drug: Hyaluronidase (H.)
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase (H.) in combination with systemic or intravesical chemotherapy
Study: 28135023
Drug: NSAIDs and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs and/or paracetamol
Study: 28135023
Drug: Both NSAIDs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both NSAIDs and paracetamol
Study: 26249767
Drug: LEVO 200
Normalized name: Stalevo 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEVO 200 µg once-daily
Study: 26249767
Drug: LEVO 200
Normalized name: Stalevo 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEVO 200 µg twice-daily
Study: 26249767
Drug: LEVO 200
Normalized name: Stalevo 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEVO 200 µg once-daily vs LEVO 200 µg twice-daily
Study: 19857150
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy with low-molecular-weight heparins
Study: 19857150
Drug: VTE prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTE prophylaxis and/or prompt treatment
Study: 15272643
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg/day (group A)
Study: 9549924
Drug: CMV‐IgG 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV‐IgG 100 mg/kg/week
Study: 9549924
Drug: HDIgG 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDIgG 400 mg/kg/week
Study: 8172750
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (pre-existing condition)
Study: 2830688
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant interferon-alpha-2C (rIFNa2C)
Study: 21849980
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial magnetic stimulation (TMS) at 10 Hz, specific details on dosage and duration not available.
Study: 12687650
Drug: MTHFR(C677T) genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTHFR(C677T) genotype CC
Study: 12742280
Drug: Tezosentan (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (25 mg/h for 1 h, then 50 mg/h for 23 to 47 h)
Study: 1734558
Drug: Intermittent feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent feeding (1-hourly, 2-hourly, 3-hourly)
Study: 6143868
Drug: 3 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus seven monthly HBIg injections
Study: 6143868
Drug: 3 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 micrograms heat-inactivated hepatitis B vaccine at birth and at 1, 2, and 6 months, plus one HBIg injection at birth
Study: 6143868
Drug: Only the
Normalized name: Product containing only theophylline (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only the vaccine at months 0, 1, 2, and 6
Study: 6143868
Drug: Placebos for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos for both vaccine and HBIg
Study: 3525266
Drug: Intensive conventional
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive conventional insulin therapy (ICT)
Study: 29031905
Drug: Tesamorelin, 2mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesamorelin, 2mg daily for six months
Study: 19916292
Drug: Acupoint-catgut implantation
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint-catgut implantation (once every two weeks for the first 6 treatments, then once a month for 1 year)
Study: 19916292
Drug: Massage (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage (20 mm, once daily for 1 year)
Study: 16491584
Drug: 5% inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% inhaled CO2 during tilt
Study: 15270743
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with lansoprazole plus amoxicillin and tinidazole
Study: 15270743
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with amoxicillin and tinidazole
Study: 8995552
Drug: 0.06 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/m2 rhTNF‐alpha intraperitoneally after drainage of fluid
Study: 8353072
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, adriamycin 50 mg/m2, ifosfamide 5 G/m2) for 6 cycles at monthly intervals
Study: 8353072
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose chemotherapy (cyclophosphamide 300 mg/m2, carboplatin 150 mg/m2, adriamycin 25 mg/m2, ifosfamide 2.5 G/m2) for 12 cycles at monthly intervals
Study: 8353072
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose chemotherapy (300 mg/m2 cyclophosphamide and 150 mg/m2 carboplatin) for 12 cycles
Study: 8353072
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose chemotherapy (600 mg/m2 cyclophosphamide and 300 mg/m2 carboplatin) for 6 cycles
Study: 8353072
Drug: Both standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both standard and low dose cycles of chemotherapy
Study: 3301453
Drug: Epomediol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epomediol (200 mg three times daily for 30 days)
Study: 29104179
Drug: Six-month dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-month dual antiplatelet therapy (DAPT)
Study: 23746564
Drug: Bicarbonate loading
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate loading (300 mg∙kg⁻¹)
Study: 21344002
Drug: 2% PRO2000/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% PRO2000/5 microbicide gel
Study: 18267977
Drug: Short intravenous
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short intravenous treatment (3 days of intravenous ceftriaxone followed by 5 days of oral antibiotics)
Study: 18267977
Drug: Long intravenous
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long intravenous treatment (8 days of intravenous ceftriaxone)
Study: 16584432
Drug: CAD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD treatment
Study: 11096148
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly subcutaneous epoetin beta (n=118)
Study: 11096148
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or three times weekly subcutaneous epoetin beta (control group, n=40)
Study: 11096148
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly subcutaneous epoetin beta
Study: 11096148
Drug: Two or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two or three times weekly subcutaneous epoetin beta (control group)
Study: 31460597
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion program (intervention group)
Study: 29268886
Drug: Switched dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched dual antiplatelet therapy (DAPT)
Study: 29268886
Drug: Unchanged dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged dual antiplatelet therapy (DAPT)
Study: 25844616
Drug: Topical epidermal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epidermal growth factor (EGF) serum applied twice daily for 12 weeks
Study: 19003590
Drug: Selective photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective photodynamic therapy (PDT) using an optic fiber with an 810‐nm diode laser after indocyanine green (ICG) application
Study: 15215810
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment combined with streptokinase
Study: 10842419
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 400 mg of vitamin E and 500 mg of vitamin C
Study: 9219199
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (0.3 g.kg‐1)
Study: 8378411
Drug: Maprotiline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (up to 75 mg/d)
Study: 22471126
Drug: Auricular stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular stimulator in the cavum concha for 30 min, once daily for 3 months
Study: 19834313
Drug: Metformin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1 g b.d, n=26)
Study: 19834313
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OCP) (35 g ethinyl estradiol/2 mg cyproterone acetate, n=30)
Study: 18030228
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg and 40 mg once daily for 8 weeks
Study: 15803017
Drug: Ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.1 mg/kg)
Study: 10195516
Drug: 0.1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL/kg 1% lidocaine i.v.
Study: 10195516
Drug: 0.1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL/kg isotonic sodium chloride solution (placebo control)
Study: 6140939
Drug: Prizidilol hydrochloride
Normalized name: Chlorpromazine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prizidilol hydrochloride (400 mg)
Study: 30702971
Drug: Celecoxib with
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib with neoadjuvant chemotherapy (NAC)
Study: 24335026
Drug: Metformin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (250 mg 3 times a day for 7 days)
Study: 22972538
Drug: Delayed-release doxylamine-pyridoxine
Normalized name: doxylamine / pyridoxine Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release doxylamine-pyridoxine (Diclectin)
Study: 15460211
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine (IbuLys) 400 mg (two tablets of Dolormin as a single dose)
Study: 15460211
Drug: Ibuprofen (Ibu)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen (Ibu) 400 mg (two tablets as a single dose)
Study: 11433224
Drug: VPA-985 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPA-985 (50 or 100 mg twice daily)
Study: 8179848
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 or 25 mg)
Study: 8179848
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nebivolol and hydrochlorothiazide
Study: 8179848
Drug: Nebivolol 10
Normalized name: nebivolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 10 mg combined with hydrochlorothiazide 25 mg
Study: 3069520
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg choline theophyllinate administered orally every 12 h for 7 days